MedTrace Logo

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies

NCT00820508 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2011-11-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845 is tolerated in patients with haematological diseases and lymphoid malignancies.

Conditions

  • Hematological Disease
  • Lymphoid Malignancies

Interventions

DRUG

CHR-2845

Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days

Sponsors & Collaborators

  • Chroma Therapeutics

    lead INDUSTRY

Principal Investigators

  • Bob Löwenberg, M.D · Erasmus Medical Center

  • Gert Ossenkoppele, M.D · Amsterdam UMC, location VUmc

  • Pierre Zachee, MD · ZNA Stuivenberg

  • Norbert Vey, MD · Institut Paoli-Calmettes

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Belgium
  • France
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820508 on ClinicalTrials.gov